- Home
- VVR vs LRMR Comparison
VVR vs LRMR Comparison
Compare VVR & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVR | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.4M | 455.8M |
| IPO Year | 1998 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VVR | LRMR |
|---|---|---|
| Price | $2.98 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 945.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $2.26 |
| 52 Week High | $3.83 | $6.42 |
Technical Indicators
Market Signals| Indicator | VVR | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 51.34 |
| Support Level | $2.93 | $3.12 |
| Resistance Level | $3.08 | $3.74 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 20.70 | 74.69 |
Price Performance
Historical ComparisonAbout VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.